|
We are proud to support many oncologists in their ongoing work towards new treatments and a cure for ACC. The ACCRF research network continues to facilitate cutting-edge research and clinical trials that advance our understanding of the disease. Below are some of the most recent research publications (with ACCRF grantee authors in parentheses) detailing the latest findings in the field:
The combination of axitinib (VEGFR inhibitor) and avelumab (PD-L1 inhibitor) shows reasonable anti-tumor activity in recurrent/metastatic ACC patients. 18% of patients experienced substantial tumor shrinkage (partial responses) and 57% of patients had stable disease for 6 months or longer. Work from this group describing molecular biomarkers that predict which ACC patients are most likely to respond to axitinib plus avelumab will be presented at the ASCO 2023 meeting.
ACC that develops in different secretory glands around the body (salivary, mammary, lacrimal, skin/sweat) looks very similar at a molecular level. They all have similar gene expression and harbor many of the same gene alterations. Scientists from four ACCRF grantee institutions collaborated to find and analyze rare specimens from unusual body sites, buttressing the hypothesis that similar drugs may effectively treat ACC metastases from different primary tumor sites.
Two interrelated studies on single cell sequencing:
Analysis of individual ACC cells at their molecular level reveals differences in signaling across different cell populations within a tumor. Supported by ACCRF grants and provision of tumor specimens, these two papers describe the differences among cells within any given ACC tumor, suggesting new drugs and combinations to treat the disease. We are incredibly grateful to ACC patients who donated tumor tissue to make these—and many other—studies possible.
These and other important research papers are all listed on our Published Articles webpage.
| 
